Adlai Nortye dosed the first U.S. patient in the intermittent weekly arm of its global Phase 1 trial of AN9025.
The study evaluates AN9025 in advanced or metastatic solid tumors with RAS mutations, with daily dosing and weekly dosing arms enrolling.
Intermittent weekly dosing aims to improve tolerability and support higher dosing while maintaining anti-tumor activity, based on preclinical findings.
Initial Phase 1 dose-escalation results from the daily dosing arm are expected in 1H27, with a potential early look at the weekly arm.
ANL•
